Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer.
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333
Informations de publication
Date de publication:
10 02 2023
10 02 2023
Historique:
pubmed:
27
10
2022
medline:
10
2
2023
entrez:
26
10
2022
Statut:
ppublish
Résumé
Overexpression of c-Met protein and epidermal growth factor receptor ( This study evaluated Teliso-V (2.7 mg/kg once every 21 days) plus erlotinib (150 mg once daily) in adult patients (age ≥ 18 years) with c-Met+ NSCLC. Later enrollment required presence of an As of January 2020, 42 patients were enrolled (N = 36 efficacy-evaluable). Neuropathies were the most common any-grade adverse events reported, with 24 of 42 patients (57%) experiencing at least one event. The pharmacokinetic profile of Teliso-V plus erlotinib was similar to Teliso-V monotherapy. Median PFS for all efficacy-evaluable patients was 5.9 months (95% CI, 2.8 to not reached). ORR for Teliso-V plus erlotinib showed encouraging antitumor activity and acceptable toxicity in EGFR TKI-pretreated patients with
Identifiants
pubmed: 36288547
doi: 10.1200/JCO.22.00739
pmc: PMC9928626
doi:
Substances chimiques
Erlotinib Hydrochloride
DA87705X9K
telisotuzumab vedotin
976X9VXC3Z
ErbB Receptors
EC 2.7.10.1
Protein Kinase Inhibitors
0
Banques de données
ClinicalTrials.gov
['NCT02099058']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1105-1115Subventions
Organisme : NCI NIH HHS
ID : P30 CA093373
Pays : United States
Commentaires et corrections
Type : CommentIn
Références
Expert Rev Anticancer Ther. 2016;16(4):383-90
pubmed: 26943236
Science. 1991 Feb 15;251(4995):802-4
pubmed: 1846706
N Engl J Med. 2020 Sep 3;383(10):931-943
pubmed: 32469185
N Engl J Med. 2020 Sep 3;383(10):944-957
pubmed: 32877583
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Br J Cancer. 1996 Dec;74(12):1862-8
pubmed: 8980383
Genes Chromosomes Cancer. 2008 Dec;47(12):1025-37
pubmed: 18709663
CPT Pharmacometrics Syst Pharmacol. 2019 Aug;8(8):606-615
pubmed: 31207190
N Engl J Med. 2005 Jul 14;353(2):123-32
pubmed: 16014882
BMC Cancer. 2018 May 25;18(1):598
pubmed: 29801465
Am J Pathol. 2010 Nov;177(5):2191-204
pubmed: 20934974
Ophthalmic Plast Reconstr Surg. 2007 Jan-Feb;23(1):63-5
pubmed: 17237697
J Clin Oncol. 2018 Nov 20;36(33):3298-3306
pubmed: 30285518
Clin Cancer Res. 2021 Nov 1;27(21):5781-5792
pubmed: 34426443
Nature. 2014 Jul 31;511(7511):543-50
pubmed: 25079552
Clin Cancer Res. 2017 Feb 15;23(4):992-1000
pubmed: 27573171
Lancet Oncol. 2019 May;20(5):625-635
pubmed: 30975627
Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7
pubmed: 18093943
Clin Cancer Res. 2019 Apr 15;25(8):2403-2413
pubmed: 30425090
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Cancer Cell. 2010 Jan 19;17(1):77-88
pubmed: 20129249
PLoS One. 2020 Jul 14;15(7):e0234818
pubmed: 32663210
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):692-7
pubmed: 18180459
Invest New Drugs. 2018 Feb;36(1):121-135
pubmed: 29027591
Science. 2007 May 18;316(5827):1039-43
pubmed: 17463250
J Clin Oncol. 2013 Nov 10;31(32):4105-14
pubmed: 24101053
JCO Precis Oncol. 2017;2017(1):
pubmed: 29527595
J Thorac Oncol. 2009 Jan;4(1):5-11
pubmed: 19096300
Nature. 1984 Sep 6-11;311(5981):29-33
pubmed: 6590967
J Clin Oncol. 2018 Nov 1;36(31):3101-3109
pubmed: 30156984